Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 2236  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::Related articles
 ::  Article in PDF (328 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  Abstract
 ::  Introduction
 ::  Management of No...
 ::  Risk Stratificat...
 ::  Medical Therapy ...
 ::  Conclusion
 ::  References
 ::  Article Tables

 Article Access Statistics
    Viewed16141    
    Printed362    
    Emailed19    
    PDF Downloaded87    
    Comments [Add]    
    Cited by others 10    

Recommend this journal


 


 
  Table of Contents     
REVIEW ARTICLE
Year : 2011  |  Volume : 57  |  Issue : 2  |  Page : 161-167

Management of nonvariceal upper gastrointestinal bleeding


Gastroenterology, Department of General Medicine, Khoo Teck Puat Hospital, Singapore

Date of Submission07-Nov-2010
Date of Decision30-Nov-2010
Date of Acceptance20-Dec-2010
Date of Web Publication4-Jun-2011

Correspondence Address:
E Wee
Gastroenterology, Department of General Medicine, Khoo Teck Puat Hospital
Singapore
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0022-3859.81868

Rights and Permissions


 :: Abstract 

Nonvariceal upper gastrointestinal bleeding is unique from variceal bleeding in terms of patient characteristics, management, rebleeding rates, and prognosis, and should be managed differently. The majority of nonvariceal upper gastrointestinal bleeds will not rebleed once treated successfully. The incidence is 80 to 90% of all upper gastrointestinal bleeds and the mortality is between 5 to 10%. The causes include nonacid-related ulceration from tumors, infections, inflammatory disease, Mallory-Weiss tears, erosions, esophagitis, dieulafoy lesions, angiodysplasias, gastric antral vascular ectasia, and portal hypertensive gastropathy. Rarer causes include hemobilia, hemosuccus pancreaticus, and aortoenteric fistulas. Hematemesis and melena are the key features of bleeding from the upper gastrointestinal tract, but fresh per rectal bleeding may be present in a rapidly bleeding lesion. Resuscitation and stabilization before endoscopy leads to improved outcomes. Fluid resuscitation is essential to avoid hypotension. Though widely practiced, there is currently insufficient evidence to show that routine red cell transfusion is beneficial. Coagulopathy requires correction, but the optimal international normalized ratio has not been determined yet. Risk stratification scores such as the Rockall and Glasgow-Blatchford scores are useful to predict rebleeding, mortality, and to determine the urgency of endoscopy. Evidence suggests that high-dose proton pump inhibitors (PPI) should be given as an infusion before endoscopy. If patients are intolerant of PPIs, histamine-2 receptor antagonists can be given, although their acid suppression is inferior. Endoscopic therapy includes thermal methods such as coaptive coagulation, argon plasma coagulation, and hemostatic clips. Four quadrant epinephrine injections combined with either thermal therapy or clipping reduces mortality. In hypoxic patients, endoscopy masks allow high-flow oxygen during upper gastrointestinal endoscopy. The risk of rebleeding reduces after 72 hours. In rebleeding, repeat endoscopy is useful and persistent failure of endoscopic therapy mandates either embolization or surgery. In this review, we analyze the management of nonvariceal upper gastrointestinal bleeding with evidence from the currently published clinical trials.


Keywords: Endoscopy, GI bleeding, management, proton pump inhibitor, review, upper gastrointestinal bleeding


How to cite this article:
Wee E. Management of nonvariceal upper gastrointestinal bleeding. J Postgrad Med 2011;57:161-7

How to cite this URL:
Wee E. Management of nonvariceal upper gastrointestinal bleeding. J Postgrad Med [serial online] 2011 [cited 2018 Aug 15];57:161-7. Available from: http://www.jpgmonline.com/text.asp?2011/57/2/161/81868



 :: Introduction Top


Upper gastrointestinal bleeding can be divided into variceal bleeding and nonvariceal bleeding. This is because the patient characteristics, endoscopic management, medical management, rebleeding rates, and prognosis are different between both pathologies. Published studies from multiple countries suggest that 80 to 90% of all upper gastrointestinal bleeds are due to nonvariceal lesions. The majority are due to peptic ulcer disease. [1],[2],[3] Other causes of nonvariceal bleeding are due to nonacid-related ulceration (e.g., tumors, viral infections, inflammatory disease),  Mallory-Weiss tear More Detailss, erosions, esophagitis, dieulafoy lesions, angiodysplasias, gastric antral vascular ectasia, and portal hypertensive gastropathy. [4],[5],[6],[7] Even rarer causes are hemobilia, hemosuccus pancreaticus, and aortoenteric fistulas. [8],[9],[10],[11]

Nonvariceal upper gastrointestinal bleeding carries a mortality of between 5 to 10%. [1],[12] The majority of patients with an episode of bleeding will not rebleed once they have been treated successfully. Endoscopy is the best modality to evaluate and manage an episode of nonvariceal upper gastrointestinal bleeding as it is both effective and safe. However, as many as 7 to 16% of patients will have persistent bleeding or recurrent episodes of rebleeding during their admission. [13],[14]

Upper gastrointestinal bleeding is defined as bleeding proximal to the ligament of Treitz. This may present either as hematemesis or melena. [15] Occasionally, hemoptysis may be mistaken by the patient as hematemesis and this should be suspected by the astute physician when the upper gastrointestinal endoscopy is normal without any blood seen in the upper gastrointestinal tract. In addition, bleeding can also occur from the oral pharynx.

Patients with an upper gastrointestinal bleeding may present with melena. However, melena is also a feature of small bowel bleeding and can also present as bleeding from the right-sided colon. [16] In addition, although fresh per rectal bleeding is frequently associated with lower gastrointestinal bleeding, upper gastrointestinal bleeding can also present as fresh per rectal bleeding. This may occur when the rate of bleeding is rapid, such as that seen by an arterial bleed from a duodenal ulcer.


 :: Management of Nonvariceal Upper Gastrointestinal Bleeding Top


The initial management of any patient who has an episode of upper gastrointestinal bleeding is resuscitation. This includes stabilizing the airway, breathing, and circulation, ensuring stable hemodynamics. Patients with massive hematemesis may aspirate blood leading to respiratory compromise or may be drowsy from hypovolemic shock. Those who are hypoxemic should be administered supplemental oxygen. Patients who have high oxygen flow requirements which cannot be adequately provided by intranasal prongs may require prophylactic intubation before endoscopy. Alternatively, those who require a face mask to provide oxygen may use specially designed endoscopy masks which have one-way valves that fit an endoscope without leaking air out (e.g., Endoscopy mask, VBM Medizintechnik GmbH, Germany). These masks can provide high-flow oxygen with positive pressure during endoscopy. [17] However, suctioning of the oral cavity is not possible with the mask in place. Therefore, they are only suited for short durations of use.

Hypotensive patients require resuscitation with volume expanders. A recent Cochrane systematic review on the role of red cell transfusion in gastrointestinal bleeding failed to show any benefit of transfusion. However, the review was hampered by the small numbers of studies with incomplete data. Well-designed clinical trials on this topic are currently lacking. [18] Nonetheless, fluids such as normal saline or blood products should be given as required. One should realize that correction of hypotension is not only to maintain end-organ perfusion, but also to facilitate the administration of drugs used in conscious sedation (e.g., midazolam) during endoscopy. Benzodiazepines may aggravate hypotension and should be used with caution in a patient with a borderline normotensive blood pressure.

Coagulopathy should be corrected with blood products in a bleeding patient. Patients on anticoagulation (e.g., warfarin) or antithrombotic therapy (e.g., aspirin, dipyridamole, clopidogrel) should have their medications stopped temporarily, as the risks of continued bleeding outweigh the risks of cerebrovascular or cardiovascular thrombosis. In patients who are taking warfarin for a mechanical cardiac valve, high doses of vitamin K should not be given. Rather, fresh frozen plasma with or without low-dose vitamin K (1-2 mg) is preferred. [19] One should note that the optimal target international normalized ratio (INR) for a bleeding patient has yet to be determined. INR levels below 1.5 do not require further correction. For patients with supra-therapeutic INR values, endoscopy should be postponed until the coagulopathy is corrected, if possible. Patients with a therapeutic INR of 2 and below do not usually need to wait for the coagulopathy to be corrected before endoscopy. [20] For patients who are on antiplatelet therapy, their medications should be stopped. Platelets can be transfused if needed to correct the functional platelet defect. Those with recently inserted cardiac stents (within one year), especially drug-eluting stents, should have their case discussed with the cardiologist. [21]


 :: Risk Stratification of a Nonvariceal Upper Gastrointestinal Bleed Top


In determining the urgency of treatment during an episode of upper gastrointestinal bleeding and the prognosis of the patient, a risk stratification score may be used. There are several scores, among which the Rockall and the Glasgow-Blatchford scores are frequently used. [22],[23],[24] Risk stratification scores predict the need for intervention, risk of rebleeding, and risk of mortality.

The Rockall score is a prognostic score which was developed to determine the risk of rebleeding and death from an episode of upper gastrointestinal bleed [Table 1]. [23] This score is based on the patient's age, presence of shock, coexisting illness, diagnosis, and stigmata of hemorrhage. Therefore, before the Rockall score can be calculated, the endoscopy must first be performed. Patients with a score of 2 or below are at low risk of rebleeding and death. Although one validation study found the prediction of risk of rebleeding to be unsatisfactory with the Rockall score, another large retrospective study found the score useful in influencing the management of patients based on their severity of illness. [25],[26]
Table 1: Rockall score

Click here to view


The Glasgow-Blatchford score [Table 2] is another frequently utilized score for upper gastrointestinal bleeding. It can be calculated by tallying up the points for each of the following criteria: systolic blood pressure, blood urea nitrogen, hemoglobin, and the presence of tachycardia, melena, syncope, liver, or cardiac diseases. [22] High scores carry a graver prognosis and require intervention, as compared with lower scores. One advantage of this score is that it can be calculated when the patient presents to the physician. Unlike the Rockall score, both endoscopy and the diagnosis are not required for the Glasgow-Blatchford score. The Glasgow-Blatchford score has been used successfully to stratify patients into different risk groups. Those with low scores can be managed outpatient, whereas those with higher scores are admitted and treated in hospital. It has also been used to determine the need for intervention and the risk of mortality. [27]
Table 2: Glasgow-Blatchford score

Click here to view



 :: Medical Therapy of Nonvariceal Upper Gastrointestinal Bleeding Top


Intravenous proton pump inhibitors (PPI) should be initiated in any patient suspected to have bleeding from the upper gastrointestinal tract. Intravenous PPIs are available as various preparations (e.g., omeprazole, pantoprazole, esomeprazole) and there is no current consensus which favors the use of one drug over the other.

PPI therapy is given as an intravenous loading dose, followed by an infusion. PPI should be started even before endoscopy is performed, but should not delay the endoscopy. [20] High-dose infusion PPI is believed to promote clot stability, facilitating hemostasis by raising the intragastric pH. [28],[29],[30] Starting a PPI infusion before endoscopy has been shown in clinical trials and a recent Cochrane systematic review to downstage the high-risk bleeding stigmata seen in endoscopy. PPI before endoscopy leads to a faster resolution of bleeding. [31],[32] Therefore, even though no mortality benefit is seen in early PPI initiation, it is beneficial to the patient because less therapy is required. [20],[33]

During upper gastrointestinal endoscopy, bleeding lesions are graded based on the Forest classification [Table 3]. [34] Lesions which are Forest II b or greater (i.e., Forest IIa, Ib, Ia) should continue with PPI infusion, whereas lesions which are Forest II c and below can be treated with oral PPI therapy. The commonly used PPI doses are below:

  1. Intravenous omeprazole 80 mg as a loading dose, followed by an infusion of 8 mg/h.
  2. Intravenous pantoprazole 80 mg as a loading dose, followed by an infusion of 8 mg/h.
  3. Intravenous esomeprazole 80 mg as a loading dose, followed by an infusion of 8 mg/h.
Table 3: Forest classification

Click here to view
The infusion is continued for 72 hours before it is converted to an oral formulation. The rationale is that high-risk lesions take 72 hours to become low-risk lesion. [35],[36] The regimen of administering PPI in this manner is supported by a randomized clinical trial, which showed that patients receiving PPI had lower rebleeding rates, transfusion requirements, and hospitalization stay after endoscopic therapy. [37] In addition, the risk of rebleeding is highest in the first 72 hours. Therefore, if a patient has another episode of rebleeding, PPI infusion should not be stopped after the initial 72 hours. PPI should be continued for a longer duration, before conversion to an oral formulation. The duration of extension of PPI infusion has not been defined in clinical trials yet.

In the event that the patient has an allergy to PPI, histamine-2 receptor antagonists such as intravenous ranitidine can be given. However, the acid suppression of histamine-2 receptor antagonists is inferior to PPI infusion. [38],[39] In a multicenter randomized controlled trial, intravenous PPI was superior to intravenous histamine-2 receptor antagonist in the treatment of arterial spurters. [40] Therefore, with the availability of PPI, histamine-2 receptor antagonists cannot be recommended unless PPI are contraindicated. [20] Histamine-2 receptor antagonist such as ranitidine can be given as intravenous ranitidine 50 mg 6 hourly or intravenous ranitidine 50 mg as a loading dose, followed by 6.25 mg per hour infusion (a total of 150 mg per day).

A prokinetic is a useful adjunct to endoscopy. It is helpful in patients who have large amounts of blood clots in their stomach (as seen endoscopically or suspected when persistent hematemesis occurs). It is also useful in patients who have recently consumed food and require urgent endoscopy. [41] Prokinetic therapy should be used only when indicated and not routinely. Drugs such as intravenous metoclopramide or erythromycin may be administered. Intravenous metoclopramide is prescribed as a bolus dose of 10 mg. Intravenous erythromycin is given at a dose of 3 mg per kg body weight. Usually, 250 mg of intravenous erythromycin is diluted in 100 ml of saline and infused over 15 minutes or longer. Erythromycin should be avoided, if possible, in patients with a prolonged corrected QT on electrocardiography, due to the risks of triggering life-threatening ventricular arrhythmias.

Timing of endoscopy

After resuscitation and medical therapy, endoscopic therapy should be performed. Proper preparation before endoscopy can lower the risk of complications of emergency endoscopy. [13],[14] Once ready, endoscopy should be done earlier, rather than later. Early endoscopy (within 24 hours) for nonvariceal upper gastrointestinal bleeding has been shown in a systemic analysis to reduce the length of hospitalization, lower costs, lower transfusion requirements, and lead to better patient outcomes. [42] However, factors such as the availability of expertise, staff, and equipment, especially after duty hours, vary from institution to institution and may mandate a delay in endoscopy. Where possible, endoscopy should not be delayed longer than 24 hours. [20] The type of endoscopic management depends on the stigmata of hemorrhage seen. This can be graded according to the Forest classification [Table 3]. [34] Endoscopic therapy is advocated in lesions which present with active bleeding (spurting or oozing), nonbleeding visible vessels, or adherent clots. These lesions carry a higher risk of rebleeding as compared with an ulcer with a hematin spot. They are graded as Forest II b and above. A randomized control trial showed that treating nonbleeding lesions such as a visible vessel or adherent clot endoscopically combined with PPI therapy was superior to PPI therapy alone in preventing rebleeding. [43] Evidence for the removal of adherent clots is weak, although it has been advocated in a recent consensus meeting on upper gastrointestinal hemorrhage. [20] When an adherent clot is seen, it is advisable to inject epinephrine at 4 quadrants around the clot before removing it. Clot removal can be performed by flushing it vigorously, displacing it with an instrument, sucking at it with the endoscope, or snaring the clot away. [44] Snaring the clot is an atraumatic method if done correctly. Guillotine cold snaring is performed by gently opening and closing the snare over the clot. This fragments the clot and may reveal an underlying vessel. One should be extremely cautious not to snare a protuberant vessel.

Clean base ulcers and ulcers with a flat red spot or necrotic base do not require endoscopic therapy because they are at very low risk of rebleeding. These lesions (graded Forest II c and below) can be treated with medical therapy alone. If a bleeding source is identified, hemostasis is applied through one of several methods.

Epinephrine injection

Epinephrine injection is a useful method to induce hemostasis for both arterial and venous bleeding. However, the vasoconstrictive and tamponading effects of epinephrine are temporary. Meta-analysis of randomized controlled trials has shown clearly that when epinephrine injection therapy is combined with a second hemostatic modality, the rebleeding, emergency surgery, and mortality rates are reduced. This benefit is irrespective of the type of second modality used. Hence, it is recommended to combine epinephrine injection therapy together another hemostatic method. [45],[46] Epinephrine injection is performed by injecting a solution of epinephrine (1 : 10 000 concentration) in aliquots of 1.0 ml around the bleeding source. Larger volumes of epinephrine and repeated injections may be required if the bleeding persists. The assistant should verbalise the amount of epinephrine injected so that the endoscopist is aware of the amount delivered. This is performed in 4 quadrants before assessing for a response. A response is indicated by temporary cessation of bleeding and accompanied with blanching of the surrounding mucosa into a pale whitish-red color. This indicates that vasospasm has been successfully induced by epinephrine. The endoscopist should not inject epinephrine directly into a vessel or bleeding point, as this may cumulate in sudden tachycardia, hypertension, and a restless patient.

Thermal therapy

The aim of thermal therapy is to coagulate the vessel. This can be performed with bipolar/multipolar electrocoagulation, heater probe, argon plasma coagulation, or laser. Thermal therapy with the heater probe and electrocoagulation works through the mechanism of coaptive coagulation of the vessel. Therefore, it is important to apply firm pressure against the vessel when using both these thermal therapies. The heater probe is used with low-power settings of 15 to 30 J. Sometimes, several pulses of the heater probe are required, before the vessel is ablated. Power settings in the duodenum should be lower than settings in the stomach where the gastric walls are thicker. After coagulation, a shallow depression remains where therapy was applied, and the vessel will be absent. Further therapy is required if bleeding persists, but will lead to deeper depressions. Hence, thermal therapy is unsuitable when deep cavitating ulcers are present, especially in the duodenum or small bowel, as there is a genuine risk of causing perforation.

Bipolar/multipolar electrocoagulation probes are safer than the older monopolar probes. This is because the depth of thermal therapy is shallower and more predictable. Electrocoagulation generates heat when electricity conducts through tissues with electrical resistance. Multipolar probes are usually large 10F probes and used at 30 to 40 W for a duration of up to 10 seconds.

Thermal therapy is particularly useful in treating lesions with oozing edges without a visible vessel. It is also useful in constricted areas of the gastrointestinal tract where there is limited distance between the endoscope and the lesion, preventing deployment of a clip. However, heater probes are not useful in targeting vessels when the plane of the lesion is almost parallel with the probe, since such an orientation would not allow enough pressure to tamponade the vessel during coaptive coagulation.

Argon plasma coagulation

Unlike other thermal therapies, the argon plasma coagulation does not require tissue contact. Argon plasma coagulation causes tissue coagulation when electricity is conducted across argon gas emitted by the catheter. [47],[48] As such, the tissue damage is up to a depth of 2 to 3 mm only. [49] Because contact is not needed, argon plasma coagulation is useful for tangential lesions which are oozing.

Argon plasma coagulation is not useful when bleeding is occurring from a spurting vessel. In such cases, coaptive thermal coagulation or clipping is required. Argon plasma coagulation is useful for lesions which ooze, such as oozing from a raw surface of a gastric tumor, oozing from edges of ulcers or vascular lesions such as angiodysplasia or gastric antral vascular ectasia. Argon plasma coagulation is also useful for hemostasis in areas where the gastrointestinal wall layer is thin, such as in the small bowel and colon, since it burns superficially. As argon plasma coagulation involves unipolar cautery, one should be cautious in patients with an implantable cardio-defibrillator or pacemaker. [50]

Endoscopic clipping

Endoscopic clipping is a useful and safe method of hemostasis. This requires the assistance of a nurse who should be familiar with the loading and deployment of the clip. Clips are available as preloaded sets too, which are more convenient to use in the emergent setting of active bleeding. Frequently, multiple clips are required due to poor positioning or inadequate hemostasis. Therefore, it is crucial to obtain good positioning before deployment of the clip. The targeted vessel should always be visible. Application of the clip blindly, with blood obscuring the vessel, is usually a futile process. To obtain good positioning, several centimeters of distance between the endoscope and the vessel are required for the clip to be advanced and opened fully. Clips should be firmly opposed against the mucosa with the vessel between the prongs, before it is deployed. If bleeding persists, further clips can be placed or thermal therapy applied.

Endoscopic clipping has been shown to be superior to epinephrine injection alone in treating nonvariceal upper gastrointestinal bleeding. However, endoscopic clipping is neither superior nor inferior to thermal therapy in terms of rebleeding, surgical rates, or mortality. [51] Endoscopic clipping may be difficult in locations such as the posterior wall of the gastric body, lesser curve, and the posterior wall of the duodenal bulb. Hence, the choice of applying endoscopic clipping over thermal therapy should be based on the ease of application of therapy (which may be determined by the site of the bleeding), familiarity with the modality of therapy, potential contraindication to further thermal injury (e.g., deep ulceration in the duodenum with concerns of inducing perforation), type of stigmata of hemorrhage (oozing edges are more appropriately treated with thermal therapy), and coagulation status (thermal therapy may aggravate bleeding in severe coagulopathy).

Failure of endoscopic therapy

In patients who rebleed after the initial endoscopy, there is a role to repeat endoscopy again. [20] Otherwise, there is usually no necessity for a re-look endoscopy. Endoscopic retreatment is comparable with surgical intervention in patients who rebleed in terms of hospitalization duration, blood transfusion requirements, and mortality. Surgery is advocated when nonvariceal upper gastrointestinal bleeding cannot be controlled endoscopically or if the patient is persistently hemodynamically unstable. [52] Patients with persistent hypotension or large ulcers greater than 2 cm are likely to fail repeat endoscopy and may benefit from surgery. [53] Surgery is also indicated if a complication such as a perforation is present.

In patients who are deemed unfit for surgery, an alternative is percutaneous angiogram and selective embolization. Embolization is performed with the use of coils, alcohol, cyanoacrylic glue, gelatin sponges, or polyvinyl. [54] Complications of embolization include bowel ischemia, infarction of the stomach, liver, and spleen, and subsequent duodenal stenosis. [55],[56]


 :: Conclusion Top


The management of upper gastrointestinal bleeding is divided into nonvariceal and variceal bleeding. Prognostic markers, such as the Glasgow-Blatchford score, can aid in deciding on the appropriate timing of endoscopy. [22],[27] Adequate resuscitation before endoscopy leads to better endoscopic outcomes. [13],[14] PPI therapy started early downstages the high-risk bleeding stigmata. [20] In nonvariceal bleeding lesions, epinephrine should be injected, followed by either thermal therapy or clipping. [45],[46] When rebleeding occurs, endoscopy is useful, [18] failing which surgery or embolization should be considered. [52],[53],[54]

 
 :: References Top

1.Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004;99:1238-46.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.Anand CS, Tandon BN, Nundy S. The causes, management and outcome of upper gastrointestinal haemorrhage in an Indian hospital. Br J Surg 1983;70:209-11.  Back to cited text no. 2
[PUBMED]    
3.Morgan AG, Clamp SE. O.M.G.E. International Upper Gastro-intestinal Bleeding Survey 1978-1982. Scand J Gastroenterol 1984;95:41-58.  Back to cited text no. 3
    
4.Kumar A, Mishra SR, Sharma P, Sharma BC, Sarin SK. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: A study of 254 cirrhotics. J Clin Gastroenterol 2010;44:294-300.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Rana SS, Bhasin DK, Gupta R, Yadav TD, Gupta V, Singh K. Periampullary Dieulafoy's lesion: An unusual cause of gastrointestinal bleeding. JOP 2010;11:266-9.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  
6.Abraham P, Mukerji SS, Desai DC, Joshi AG. Dieulafoy lesion in mid-esophagus with esophageal varices. Indian J Gastroenterol 2004;23:220-1.  Back to cited text no. 6
[PUBMED]    
7.Shah AK, Banerjee D, Gambhir RP, Chaudhry R. Mallory-Weiss tear: use of recombinant factor VIIa for exsanguinating bleed. Trop Gastroenterol 2009;30:226-7.  Back to cited text no. 7
[PUBMED]    
8.Vimalraj V, Kannan DG, Sukumar R, Rajendran S, Jeswanth S, Jyotibasu D, et al. Haemosuccus pancreaticus: Diagnostic and therapeutic challenges. HPB (Oxford) 2009;11:345-50.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Moses V, Keshava SN, Wann VC, Joseph P, Sitaram V. Cystic artery pseudoaneurysm after laparoscopic cholecystectomy presenting as haemobilia: A case report. Trop Gastroenterol 2008;29:107-9.  Back to cited text no. 9
[PUBMED]    
10.Ray G, Banerjee PK, Ghoshal UC, Dhar K, Pal BB, Biswas AD, et al. Etiology and management of obscure gastrointestinal bleed-an appraisal from eastern India. Indian J Gastroenterol 2001;20:90-3.  Back to cited text no. 10
[PUBMED]    
11.Thomson VS, Gopinath KG, Joseph E, Joseph G. Primary aorto-enteric fistula: A rare complication of abdominal aortic aneurysm. J Postgrad Med 2009;55:267-9.  Back to cited text no. 11
[PUBMED]  Medknow Journal  
12.Lim CH, Vani D, Shah SG, Everett SM, Rembacken BJ. The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: A prospective cohort study. Endoscopy 2006;38:581-5.  Back to cited text no. 12
[PUBMED]  [FULLTEXT]  
13.Loperfido S, Baldo V, Piovesana E, Bellina L, Rossi K, Groppo M, et al. Changing trends in acute upper-GI bleeding: A population-based study. Gastrointest Endosc 2009;70:212-24.  Back to cited text no. 13
[PUBMED]  [FULLTEXT]  
14.Van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008;22:209-24.  Back to cited text no. 14
[PUBMED]    
15.Singhal D, Kakodkar R, Nundy S. Management protocol for acute gastrointestinal bleeding. J Indian Med Assoc 2006;104:226-30.  Back to cited text no. 15
    
16.Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;331:717-27.  Back to cited text no. 16
[PUBMED]  [FULLTEXT]  
17.Somri M, Gaitini L, Yanovski B, Tome R, Resnikov I, Karsh K, et al. Flexible upper videoendoscopy through a modified endoscopy mask in infants and young children. J Pediatr Gastroenterol Nutr 2009;49:191-5.  Back to cited text no. 17
[PUBMED]  [FULLTEXT]  
18.Jairath V, Hearnshaw S, Brunskill SJ, Doree C, Hopewell S, Hyde C, et al. Red cell transfusion for the management of upper gastrointestinal haemorrhage. Cochrane Database Syst Rev 2010;8:006613.  Back to cited text no. 18
    
19.Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am J Coll Cardiol 2008;52:1-142.  Back to cited text no. 19
    
20.Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13.  Back to cited text no. 20
[PUBMED]    
21.Anderson MA, Ben-Menachem T, Gan SI, Appalaneni V, Banerjee S, Cash BD, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009;70:1060-70.  Back to cited text no. 21
[PUBMED]  [FULLTEXT]  
22.Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000;356:1318-21.  Back to cited text no. 22
[PUBMED]  [FULLTEXT]  
23.Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21.  Back to cited text no. 23
[PUBMED]  [FULLTEXT]  
24.Vreeburg EM, Terwee CB, Snel P, Rauws EA, Bartelsman JF, Meulen JH, et al. Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. Gut 1999;44:331-5.  Back to cited text no. 24
[PUBMED]  [FULLTEXT]  
25.Kim BJ, Park MK, Kim SJ, Kim ER, Min BH, Son HJ, et al. Comparison of scoring systems for the prediction of outcomes in patients with nonvariceal upper gastrointestinal bleeding: A prospective study. Dig Dis Sci 2009;54:2523-9.  Back to cited text no. 25
[PUBMED]  [FULLTEXT]  
26.Soncini M, Triossi O, Leo P, Magni G, Bertelè AM, Grasso T, et al. Management of patients with nonvariceal upper gastrointestinal hemorrhage before and after the adoption of the Rockall score, in the Italian Gastroenterology Units. Eur J Gastroenterol Hepatol 2007;19:543-7.  Back to cited text no. 26
    
27.Stanley AJ, Ashley D, Dalton HR, Mowat C, Gaya DR, Thompson E, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: Multicentre validation and prospective evaluation. Lancet 2009;373:42-7.  Back to cited text no. 27
[PUBMED]  [FULLTEXT]  
28.Ghassemi KA, Kovacs TO, Jensen DM. Gastric acid inhibition in the treatment of peptic ulcer hemorrhage. Curr Gastroenterol Rep 2009;11:462-9.  Back to cited text no. 28
[PUBMED]    
29.Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: An in vitro study. Gut 1989;30:1704-7.  Back to cited text no. 29
[PUBMED]  [FULLTEXT]  
30.Geus WP. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol suppl 2000;232:10-20.  Back to cited text no. 30
    
31.Lau JY, Leung WK, Wu JC, Chan FK, Wong VW, Chiu PW, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631-40.  Back to cited text no. 31
[PUBMED]  [FULLTEXT]  
32.Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;7:005415.  Back to cited text no. 32
    
33.Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006;4:005415.  Back to cited text no. 33
    
34.Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974;2:394-7.  Back to cited text no. 34
[PUBMED]    
35.Lau JY, Chung SC, Leung JW, Lo KK, Yung MY, Li AK. The evolution of stigmata of hemorrhage in bleeding peptic ulcers: a sequential endoscopic study. Endoscopy 1998;30:513-8.  Back to cited text no. 35
[PUBMED]  [FULLTEXT]  
36.Hsu PI, Lin XZ, Chan SH, Lin CY, Chang TT, Shin JS, et al. Bleeding peptic ulcer-risk factors for rebleeding and sequential changes in endoscopic findings. Gut 1994;35:746-9.  Back to cited text no. 36
[PUBMED]  [FULLTEXT]  
37.Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310-6.  Back to cited text no. 37
[PUBMED]  [FULLTEXT]  
38.Huggins RM, Scates AC, Latour JK. Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding. Ann Pharmacother 2003;37:433-7.  Back to cited text no. 38
[PUBMED]  [FULLTEXT]  
39.Hsu PI, Lo GH, Lo CC, Lin CK, Chan HH, Wu CJ, et al. Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers. World J Gastroenterol 2004;10:3666-9.  Back to cited text no. 39
[PUBMED]  [FULLTEXT]  
40.Van Rensburg C, Barkun AN, Racz I, Fedorak R, Bornman PC, Beglinger C, et al. Clinical trail: Intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: A multicentre, multinational, randomized trial. Aliment Pharmacol Ther 2009;29:497-507.  Back to cited text no. 40
[PUBMED]  [FULLTEXT]  
41.Alan N. Barkun, Marc Bardou, Ian M. Gralnek. Erythromycin and other prokinetics in acute upper gastrointestinal bleeding? A meta-analysis. Gastroenterology 2009;136;A-636.  Back to cited text no. 41
    
42.Spiegel BM, Vakil NB, Ofman JJ. Endoscopy for acute nonvariceal upper gastrointestinal tract hemorrhage: Is sooner better? A systematic review. Arch Intern Med 2001;161:1393-404.  Back to cited text no. 42
[PUBMED]  [FULLTEXT]  
43.Sung JJ, Chan FK, Lau JY, Yung MY, Leung WK, Wu JC, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: A randomized comparison. Ann Intern Med 2003;139:237-43.  Back to cited text no. 43
[PUBMED]    
44.Jensen DM, Kovacs TO, Jutabha R, Machicado GA, Gralnek IM, Savides TJ, et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002;123:407-13.  Back to cited text no. 44
[PUBMED]  [FULLTEXT]  
45.Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: An evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009;7:33-47.  Back to cited text no. 45
[PUBMED]  [FULLTEXT]  
46.Vergara M, Calvet X, Gisbert JP. Epinephrine injection versus epinephrine injection and a second endoscopic method in high risk bleeding ulcers. Cochrane Database Syst Rev 2007;2:005584.  Back to cited text no. 46
    
47.Farin G, Grund KE. Technology of argon plasma coagulation with particular regard to endoscopic applications. Endosc Surg Allied Technol 1994;2:71-7.  Back to cited text no. 47
[PUBMED]    
48.Malick KJ. Clinical applications of argon plasma coagulation in endoscopy. Gastroenterol Nurs 2006;29:386-91.  Back to cited text no. 48
[PUBMED]  [FULLTEXT]  
49.Johanns W, Luis W, Janssen J, Kahl S, Greiner L. Argon plasma coagulation (APC) in gastroenterology: experimental and clinical experiences. Eur J Gastroenterol Hepatol 1997;9:581-7.  Back to cited text no. 49
[PUBMED]    
50.Petersen BT, Hussain N, Marine JE, Trohman RG, Carpenter S, Chuttani R, et al. Endoscopy in patients with implanted electronic devices. Gastrointest Endosc 2007;65:561-8.  Back to cited text no. 50
[PUBMED]  [FULLTEXT]  
51.Sung JJ, Tsoi KK, Lai LH, Wu JC, Lau JY. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: A meta-analysis. Gut 2007;56:1364-73.  Back to cited text no. 51
[PUBMED]  [FULLTEXT]  
52.Imhof M, Ohmann C, Röher HD, Glutig H; DUESUC study group. Endoscopic versus operative treatment in high-risk ulcer bleeding patients- results of a randomised study. Langenbecks Arch Surg 2003;387:327-36.  Back to cited text no. 52
    
53.Lau JY, Sung JJ, Lam YH, Chan AC, Ng EK, Lee DW, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999;340:751-6.  Back to cited text no. 53
[PUBMED]  [FULLTEXT]  
54.Sam K. Kim, Vinay Duddalwar. Failed endoscopic therapy and the interventional radiologist: Non-variceal upper gastrointestinal bleeding. Tech Gastrointest Endosc 2005;7:148-155.  Back to cited text no. 54
    
55.Ljungdahl M, Eriksson LG, Nyman R, Gustavsson S. Arterial embolisation in management of massive bleeding from gastric and duodenal ulcers. Eur J Surg 2002;168:384-90.  Back to cited text no. 55
[PUBMED]    
56.Poultsides GA, Kim CJ, Orlando R 3rd, Peros G, Hallisey MJ, Vignati PV. Angiographic embolization for gastroduodenal hemorrhage: Safety, efficacy, and predictors of outcome. Arch Surg 2008;143:457-61.  Back to cited text no. 56
[PUBMED]  [FULLTEXT]  



 
 
    Tables

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Role of Medical Therapy for Nonvariceal Upper Gastrointestinal Bleeding
Kyle J. Fortinsky,Marc Bardou,Alan N. Barkun
Gastrointestinal Endoscopy Clinics of North America. 2015; 25(3): 463
[Pubmed] | [DOI]
2 Rockall score in predicting outcomes of elderly patients with acute upper gastrointestinal bleeding
Wang, C.-Y. and Qin, J. and Wang, J. and Sun, C.-Y. and Cao, T. and Zhu, D.-D.
World Journal of Gastroenterology. 2013; 19(22): 3466-3472
[Pubmed]
3 Mortality and need of surgical treatment in acute upper gastrointestinal bleeding: A one year study in a tertiary center with a 24 hours / day-7 days / week endoscopy call. Has anything changed?
Boĺianu, A.M. and Matei, D. and Tanĺău, M. and Acalovschi, M.
Chirurgia (Romania). 2013; 108(3): 312-318
[Pubmed]
4 Emergency interventional embolization for acute life - Threatening massive bleeding in gastrointestinal tract
Xu, W. and Li, Y. and Zhou, T.-Y. and Tan, J. and Shi, Z.-X. and Wang, H.-H.
Journal of Interventional Radiology (China). 2013; 22(4): 330-334
[Pubmed]
5 Pharmacological therapy of non-variceal upper gastrointestinal bleeding [Farmakoterapia krwawienia pochodzenia nieżylakowego z górnego odcinka przewodu pokarmowego]
Kurek, K. and Dabrowski, A.
Pediatria i Medycyna Rodzinna. 2013; 9(1): 15-24
[Pubmed]
6 Emergent interventional therapy for massive gastrointestinal arterial hemorrhage
Xu, W. and Zhou, T.-Y. and Shi, Z.-X. and Tan, J. and Zhao, W.-J. and Wang, H.-H.
Chinese Journal of Interventional Imaging and Therapy. 2012; 9(9): 657-660
[Pubmed]
7 Diagnosis and management of nonvariceal upper gastrointestinal bleeding
Marc Bardou,Dalila Benhaberou-Brun,Isabelle Le Ray,Alan N. Barkun
Nature Reviews Gastroenterology & Hepatology. 2012; 9(2): 97
[Pubmed] | [DOI]
8 Diagnosis and management of nonvariceal upper gastrointestinal bleeding
Bardou, M., Benhaberou-Brun, D., Le Ray, I., Barkun, A.N.
Nature Reviews Gastroenterology and Hepatology. 2012; 9(2): 97-104
[Pubmed]
9 Independent predictors of in-hospital re-bleeding, need of operation and mortality in acute upper gastrointestinal bleeding
Fattahi, E., Somi, M.H., Moosapour, M.R., Fouladi, R.F.
Pakistan Journal of Biological Sciences. 2011; 14(17): 849-853
[Pubmed]
10 Independent Predictors of In-hospital Re-bleeding, Need of Operation and Mortality in Acute Upper Gastrointestinal Bleeding
E. Fattahi,M.H. Somi,M.R. Moosapour,R.F. Fouladi
Pakistan Journal of Biological Sciences. 2011; 14(17): 849
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 
Online since 12th February '04
© 2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow